Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Hemophagocytic lymphohistiocytosis as severe adverse event of antineoplastic treatment in children.

Lackner H, Urban C, Sovinz P, Benesch M, Moser A, Schwinger W.

Haematologica. 2008 Feb;93(2):291-4. doi: 10.3324/haematol.11704.

3.
4.

HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G.

Pediatr Blood Cancer. 2007 Feb;48(2):124-31.

PMID:
16937360
5.
6.

Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis.

Henzan T, Nagafuji K, Tsukamoto H, Miyamoto T, Gondo H, Imashuku S, Harada M.

Am J Hematol. 2006 Jan;81(1):59-61.

8.

Alpha-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis.

Tomaske M, Amon O, Bosk A, Handgretinger R, Schneider EM, Niethammer D.

Med Pediatr Oncol. 2002 Feb;38(2):141-2. No abstract available.

PMID:
11813188
9.

Etanercept in the treatment of macrophage activation syndrome.

Prahalad S, Bove KE, Dickens D, Lovell DJ, Grom AA.

J Rheumatol. 2001 Sep;28(9):2120-4. Erratum in: J Rheumatol 2001 Oct;28(10):2370.

PMID:
11550985
10.

Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemophagocytic lymphohistiocytosis.

Imashuku S, Hibi S, Sako M, Ishida Y, Mugishima H, Chen J, Tsunematsu Y.

Blood. 1995 Dec 15;86(12):4706-7. No abstract available.

11.

Hypercytokinemia in hemophagocytic syndrome.

Fujiwara F, Hibi S, Imashuku S.

Am J Pediatr Hematol Oncol. 1993 Feb;15(1):92-8.

PMID:
8447564
12.

Peripheral T-cell lymphoma presenting as hemophagocytic syndrome.

Chan EY, Pi D, Chan GT, Todd D, Ho FC.

Hematol Oncol. 1989 Jul-Aug;7(4):275-85.

PMID:
2786835

Supplemental Content

Support Center